KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EPS (Basic): 2009-2024

Historic EPS (Basic) for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $3.50.

  • Halozyme Therapeutics' EPS (Basic) rose 37.96% to $1.49 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.89, marking a year-over-year increase of 59.28%. This contributed to the annual value of $3.50 for FY2024, which is 64.32% up from last year.
  • According to the latest figures from FY2024, Halozyme Therapeutics' EPS (Basic) is $3.50, which was up 64.32% from $2.13 recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' EPS (Basic) ranged from a high of $3.50 in FY2024 and a low of $0.95 during FY2020.
  • Its 3-year average for EPS (Basic) is $2.37, with a median of $2.13 in 2023.
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 290.00% in 2020, then plummeted by 48.25% in 2022.
  • Halozyme Therapeutics' EPS (Basic) (Yearly) stood at $0.95 in 2020, then soared by 201.05% to $2.86 in 2021, then tumbled by 48.25% to $1.48 in 2022, then soared by 43.92% to $2.13 in 2023, then surged by 64.32% to $3.50 in 2024.